Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer

Authors: Paola Pinnarò, Stefano Arcangeli, Carolina Giordano, Giorgio Arcangeli, Fabrizio Ambesi Impiombato, Valentina Pinzi, Giuseppe Iaccarino, Antonella Soriani, Valeria Landoni, Lidia Strigari

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Background

To report the clinical outcome after a Single Shot 3D-CRT PBI (SSPBI) in breast cancer patients after conservative surgery (ClinicalTrials.gov Identifier: NCT01316328).

Methods

A dose of 18Gy (in the first 4 patients) and 21Gy (in the remaining 60 patients) was prescribed in a single session and delivered to the index area (i.e. the area of breast including the primary tumor bed and the surrounding tissue) using 3D-CRT with patients in prone position. Acute and late toxicity was assessed using the National Cancer Institute's CTC for Adverse Events. Cosmesis was defined based on modified Harvard criteria. Differences between dosimetric or clinical parameters of patients with/without G2 or more late toxicity or unsatisfactory (poor or fair) cosmetic outcome were evaluated with the Mann-Whitney test. Odds ratios and 95% confidence interval were calculated for cosmesis and fibrosis. Univariate and multivariate analyses(UVA/MVA) were used to determine covariates associated with an increase in fibrosis or fat necrosis rate.

Results

Sixty four patients were enrolled. With a median follow-up of 3 years, G2 and G3 subcutaneous fibrosis was detected in 20(31%) and in 8(13%) patients, and ≥G2 fat necrosis was observed in 2(3%) patients. Good to excellent, fair and poor cosmesis was observed in 38(59%), 23(36%) and 3(5%) patients, respectively. Based on UVA, the breast volume receiving more than 21Gy (V21Gy) was found to be a predictor of the ≥G1 or ≥G2 fibrosis/fat necrosis. Based on MVA, V21Gy was confirmed as a predictor for ≥G1 fibrosis/fat necrosis, the results correlated as a trend for ≥G2. Cosmesis was correlated with whole breast (WB) mean dose (p = 0.030).

Conclusion

Our choice of a single dose of 21Gy significantly increased the treatment related toxicity. However, this should not discourage novel SSPBI approaches with lower equivalent doses.
Appendix
Available only for authorised users
Literature
1.
Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, Salvadori B, Zucali R: Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001, 12: 997-1003. 10.1023/A:1011136326943CrossRefPubMed
2.
Fisher ER, Anderson S, Redmond C, Fisher B: Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NASBP protocol B-06. Semin Surg Oncol 1992, 8: 161-166.PubMed
3.
Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, Eberlein TJ, Mayzel K, Silver B, Harris JR: The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994, 74: 1746-1751. 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>3.0.CO;2-YCrossRefPubMed
4.
R: The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994, 74: 1746-1751. conservatively treated.Eur.J.Cancer 2001, 37:2178-2183 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>3.0.CO;2-YCrossRef
5.
Baglan KL, Sharpe MB, Jaffray D, et al.: Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys 2003,55(2):302-11. 10.1016/S0360-3016(02)03811-7CrossRefPubMed
6.
Vicini FA, Remouchamps V, Wallace M, et al.: Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003,57(5):1247-53. 10.1016/S0360-3016(03)01573-6CrossRefPubMed
7.
Vicini F, Winter K, Straube W, Wong J, Pass H, Rabinovitch R, Chafe S, Arthur D, Petersen I, McCormick B: A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys 2005,63(5):1531-7. Epub 2005 Sep 29 10.1016/j.ijrobp.2005.06.024CrossRefPubMed
8.
Formenti SC, Rosenstein B, Skinner KA, Jozsef G: T1 stage breast cancer: Adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients-Pilot feasibility study. Radiology 2002, 222: 171-178.CrossRefPubMed
9.
Polgár C, Major T, Fodor J, Németh G, Orosz Z, Sulyok Z, Udvarhelyi N, Somogyi A, Takácsi-Nagy Z, Lövey K, Agoston P, Kásler M: High dose rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: Seven year results of a comparative study. Int J Radiat Oncol Biol Phys 2004, 60: 1173-1181. 10.1016/j.ijrobp.2004.05.012CrossRefPubMed
10.
Vaidya JS, Tobias JS, Baum M, Wenz F, Kraus-Tiefenbacher U, D'souza D, Keshtgar M, Massarut S, Hilaris B, Saunders C, Joseph D: TARGeted Intraoperative radioTherapy (TARGIT):An Innovative Approach to Partial-Breast Irradiation. Semin Radiat Oncol 2005, 15: 84-91. 10.1016/j.semradonc.2004.10.007CrossRefPubMed
11.
Vicini FA, Arthur DW: Breast Brachytherapy: North American Experience. Semin Radiat Oncol 2005, 15: 108-115. 10.1016/j.semradonc.2004.10.005CrossRefPubMed
12.
Shah NM, Wazer DE: The MammoSite Balloon Brachytherapy Catheter for Accelerated Partial Breast Irradiation. Semin Radiat Oncol 2005, 15: 100-107. 10.1016/j.semradonc.2004.10.006CrossRefPubMed
13.
Pignol JP, Keller B, Rakovitch E, Sankreacha R, Easton H, Que W: First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2006, 64: 176-181. 10.1016/j.ijrobp.2005.06.031CrossRefPubMed
14.
Formenti SC: External-Beam Partial-Breast Irradiation. Semin Radiat Oncol 2005, 15: 92-99. 10.1016/j.semradonc.2004.10.008CrossRefPubMed
15.
Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S: The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005, 63: 214-223. 10.1016/j.ijrobp.2005.01.029CrossRefPubMed
16.
Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005, 6: 557-565. 10.1016/S1470-2045(05)70251-5CrossRefPubMed
17.
Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G: Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994, 5: 209-216.CrossRefPubMed
18.
Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998, 16: 3493-3501.PubMed
19.
Iaccarino G, Pinnaro P, Landoni V, Marzi S, Soriani A, Giordano C, Arcangeli S, Benassi M, Arcangeli G: Single fraction partial breast irradiation in prone position. J Exp Clin Cancer Res 2007,26(4):543-52.PubMed
20.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13: 176-181. 10.1016/S1053-4296(03)00031-6CrossRefPubMed
21.
Lövey K, Fodor J, Major T, Szabó E, Orosz Z, Sulyok Z, Jánváry L, Fröhlich G, Kásler M, Polgár C: Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy:4-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007, 69: 724-731. 10.1016/j.ijrobp.2007.03.055CrossRefPubMed
22.
Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC: Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. J Clin Oncol 27: 2816-2822.
23.
Fowler J: The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62: 672-695.CrossRef
24.
Veronesi U, Orecchia R, Luini A, Galimberti V, Zurrida S, Intra M, Veronesi P, Arnone P, Leonardi MC, Ciocca M, Lazzari R, Caldarella P, Rotmensz N, Sangalli C, Sances D, Maisonneuve P: Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 2010, 124: 141-151. 10.1007/s10549-010-1115-5CrossRefPubMed
25.
Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW: Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2006, 64: 489-495. 10.1016/j.ijrobp.2005.06.028CrossRefPubMed
26.
Kuske RR, Winter K, Arthur DW, Bolton J, Rabinovitch R, White J, Hanson W, Wilenzick RM: A phase II trial of brachytherapy alone following lumpectomy for select breast cancer:Toxicity analysis of Radiation Therapy Oncology Group 95-17. Int J Radiat Oncol Biol Phys 2006, 65: 45-51. 10.1016/j.ijrobp.2005.11.027CrossRefPubMed
27.
Chen PY, Vicini FA, Benitez P, Kestin LL, Wallace M, Mitchell C, Pettinga J, Martinez AA: Long-term cosmetic results and toxicity after accelerated partial breast irradiation. Cancer 2006, 106: 991-999. 10.1002/cncr.21681CrossRefPubMed
28.
Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB, Whitworth PW, Fine RE, Haffty BG, Arrambide LS: First analysis of patient demographics, technical reproducibility, cosmesis and early toxicity by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in 793 patients treated with accelerated partial breast irradiation (APBI). Cancer 2005, 104: 1138-1148. 10.1002/cncr.21289CrossRefPubMed
29.
Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, White J, Hedberg P, Hebert M, Arthur D, Zannis V, Quiet C, Streeter O, Silverstein M: Five year results:The initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 2007, 194: 456-462. 10.1016/j.amjsurg.2007.06.010CrossRefPubMed
30.
Berrang TS, Olivotto I, Kim DH, Nichol A, John Cho BC, Mohamed IG, Parhar T, Wright JR, Truong P, Tyldesley S, Sussman J, Wai E, Whelan T: Three-Year Outcomes of a Canadian Multicenter Study of Accelerated Partial Breast Irradiation Using Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys 2010, in press.
31.
Shaitelman SF, Kim LH, Grills IS, Chen PY, Ye H, Kestin LL, Yan D, Vicini FA: Predictors of long-term toxicity using three-dimensional conformal external beam radiotherapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2010, in press.
32.
Chen PY, Wallace M, Mitchell C, Grills I, Kestin L, Fowler A, Martinez A, Vicini F: Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2010, 76: 991-997. 10.1016/j.ijrobp.2009.03.012CrossRefPubMed
33.
Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA, Pierce LJ: Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2010, 76: 71-78. 10.1016/j.ijrobp.2009.01.041PubMedCentralCrossRefPubMed
34.
Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE: Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2009, 75: 1290-96. 10.1016/j.ijrobp.2009.01.009CrossRefPubMed
35.
Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010,376(9735):91-102. 10.1016/S0140-6736(10)60837-9CrossRefPubMed
36.
Lemanski C, Azria D, Gourgon-Bourgade S, Gutowski M, Rouanet P, Saint-Aubert B, Ailleres N, Fenoglietto P, Dubois JB: Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys 2010,76(3):698-703. 10.1016/j.ijrobp.2009.02.039CrossRefPubMed
37.
Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK: Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2010, in press.
38.
Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H: EORTC Radiation Oncology Group. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: A study based on the EORTC Trial 22881- 10882 ''boost versus no boost''. Eur J Cancer 2008, 44: 2587-99. 10.1016/j.ejca.2008.07.032CrossRefPubMed
39.
Bentzen SM, Yarnold JR: Reports of unexpected late side effects of accelerated partial breast irradiation -- radiobiological considerations. Int J Radiat Oncol Biol Phys 2010, 77: 969-973. 10.1016/j.ijrobp.2010.01.059PubMedCentralCrossRefPubMed
40.
Bentzen SM, Overgaard M, Thames HD, Christensen JJ, Overgaard J: Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol 1989, 56: 711-715. 10.1080/09553008914551941CrossRefPubMed
41.
Hall E: Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins; 2000.
42.
Steel GG: Basic clinical radiobiology. Eduard Arnold Publisher 1995.
43.
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010,362(6):513-20. 10.1056/NEJMoa0906260CrossRefPubMed
44.
The START Trialists' Group: The UK Standardisation of breast radiotherapy(START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol 2008, 9: 331-341.PubMedCentralCrossRef
45.
The START Trialists' Group: The UK Standardisation of breast radiotherapy(START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet 2008, 371: 1098-1107.PubMedCentralCrossRef
46.
Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessio D, Muti P, Blandino G, Sperduti I, Pinnarò P: Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer 2011, 11: 291. 10.1186/1471-2407-11-291PubMedCentralCrossRefPubMed
Metadata
Title
Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer
Authors
Paola Pinnarò
Stefano Arcangeli
Carolina Giordano
Giorgio Arcangeli
Fabrizio Ambesi Impiombato
Valentina Pinzi
Giuseppe Iaccarino
Antonella Soriani
Valeria Landoni
Lidia Strigari
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-155

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response

Research

Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Research

Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma

Research

Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients

Research

Intensity modulated radiotherapy for elderly bladder cancer patients

Research

Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study